← All trials

NCT04469465

Phase 3Interventional

Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.

View on ClinicalTrials.gov ↗

Timeline

Start date
Dec 31, 2020
Primary completion
Oct 31, 2022
Completion date
Dec 31, 2023
First posted
Jul 14, 2020
Last posted
Nov 20, 2020
Enrollment
84
Arms / groups
2 / —
Source
AACT · ingestion pipeline

Sponsors

Drugs studied

Indications studied

CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.